Replimune Group, Inc. (NASDAQ:REPL) CEO Sushil Patel Sells 10,000 Shares

Replimune Group, Inc. (NASDAQ:REPL) CEO Sushil Patel sold 10,000 shares of Replimune Group stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $12.42, for a total value of $124,200.00. Following the transaction, the chief executive officer now owns 202,014 shares of the company’s stock, valued at $2,509,013.88. The trade was a 4.72 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Replimune Group Stock Performance

Shares of REPL stock opened at $11.66 on Thursday. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18. The firm has a fifty day simple moving average of $12.21 and a two-hundred day simple moving average of $10.63. Replimune Group, Inc. has a 12 month low of $4.92 and a 12 month high of $17.00. The firm has a market capitalization of $797.74 million, a PE ratio of -3.82 and a beta of 1.26.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.07. Analysts forecast that Replimune Group, Inc. will post -2.91 EPS for the current fiscal year.

Institutional Investors Weigh In On Replimune Group

Institutional investors have recently bought and sold shares of the stock. Baker BROS. Advisors LP increased its stake in Replimune Group by 10.0% in the 3rd quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock valued at $121,057,000 after buying an additional 1,000,000 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Replimune Group by 575.1% in the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock valued at $28,062,000 after acquiring an additional 2,656,173 shares in the last quarter. Braidwell LP increased its position in shares of Replimune Group by 203.0% during the third quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock valued at $33,656,000 after acquiring an additional 2,057,460 shares during the last quarter. State Street Corp lifted its holdings in Replimune Group by 102.1% during the third quarter. State Street Corp now owns 2,340,042 shares of the company’s stock worth $25,647,000 after acquiring an additional 1,182,181 shares during the period. Finally, Geode Capital Management LLC grew its stake in Replimune Group by 17.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock valued at $15,657,000 after purchasing an additional 217,308 shares during the period. Institutional investors own 92.53% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on REPL. BMO Capital Markets boosted their target price on Replimune Group from $14.00 to $18.00 and gave the stock an “outperform” rating in a report on Friday, November 22nd. JPMorgan Chase & Co. increased their target price on Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 24th. Roth Mkm started coverage on Replimune Group in a research note on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price target for the company. Jefferies Financial Group increased their price objective on Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, December 4th. Finally, Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Replimune Group has an average rating of “Buy” and a consensus target price of $17.29.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.